Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.09
+1.6%
$3.42
$2.56
$7.73
$402.02M0.185.54 million shs2.85 million shs
Amgen Inc. stock logo
AMGN
Amgen
$331.70
+0.8%
$355.12
$261.43
$391.29
$179.01B0.442.67 million shs1.76 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$948.01
-2.8%
$943.90
$623.78
$1,133.95
$893.19B0.483.47 million shs3.24 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.65
-3.1%
$27.14
$21.97
$28.75
$146.36B0.3536.64 million shs37.42 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.33
-0.8%
$33.55
$22.96
$43.15
$3.64B0.722.37 million shs1.45 million shs
Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.64%+9.57%-8.58%-36.55%-42.35%
Amgen Inc. stock logo
AMGN
Amgen
+0.85%+0.57%-6.72%-13.66%+20.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.75%-1.78%-0.89%-10.32%+22.02%
Pfizer Inc. stock logo
PFE
Pfizer
-3.13%-2.65%-5.81%-5.85%+12.60%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.79%+4.43%-10.36%+10.16%+13.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.09
+1.6%
$3.42
$2.56
$7.73
$402.02M0.185.54 million shs2.85 million shs
Amgen Inc. stock logo
AMGN
Amgen
$331.70
+0.8%
$355.12
$261.43
$391.29
$179.01B0.442.67 million shs1.76 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$948.01
-2.8%
$943.90
$623.78
$1,133.95
$893.19B0.483.47 million shs3.24 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.65
-3.1%
$27.14
$21.97
$28.75
$146.36B0.3536.64 million shs37.42 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.33
-0.8%
$33.55
$22.96
$43.15
$3.64B0.722.37 million shs1.45 million shs
Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.64%+9.57%-8.58%-36.55%-42.35%
Amgen Inc. stock logo
AMGN
Amgen
+0.85%+0.57%-6.72%-13.66%+20.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.75%-1.78%-0.89%-10.32%+22.02%
Pfizer Inc. stock logo
PFE
Pfizer
-3.13%-2.65%-5.81%-5.85%+12.60%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.79%+4.43%-10.36%+10.16%+13.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.50
Moderate Buy$18.00482.52% Upside
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$357.127.66% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3328.51% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.7412.05% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.85
Moderate Buy$95.50204.82% Upside

Current Analyst Ratings Breakdown

Latest VKTX, AMGN, LLY, PFE, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Amgen Inc. stock logo
AMGN
Amgen
UpgradeHoldStrong-Buy
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Reiterated RatingBuyHold
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetNeutral$351.00 ➝ $340.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
Amgen Inc. stock logo
AMGN
Amgen
Set Price Target$332.00
(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$40K10,050.23N/AN/A$1.99 per share1.55
Amgen Inc. stock logo
AMGN
Amgen
$36.75B4.87$33.81 per share9.81$16.08 per share20.63
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B13.70$25.13 per share37.73$28.07 per share33.77
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.34$4.39 per share5.84$15.26 per share1.68
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$1.01N/AN/AN/A-214,860.98%-49.35%-41.65%5/13/2026 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$14.3723.0814.123.3320.96%137.41%13.28%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1533.6821.421.0334.98%105.77%23.76%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.588.97N/A11.83%19.44%8.41%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)

Latest VKTX, AMGN, LLY, PFE, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.25N/AN/AN/A$0.00 millionN/A
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Amgen Inc. stock logo
AMGN
Amgen
$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.01-$1.37-$0.36-$1.37N/AN/A
3/5/2026Q4 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 million
2/11/2026Q4 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.89-$1.38-$0.49-$1.38N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Amgen Inc. stock logo
AMGN
Amgen
$10.083.04%+8.27%70.15%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.73%+15.18%24.58%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.71%-13.20%131.30%16 Years
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, AMGN, LLY, PFE, and ALT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.72%5/15/20265/15/20266/10/2026
3/4/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.66%5/15/20265/15/20266/5/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.15
18.55
18.55
Amgen Inc. stock logo
AMGN
Amgen
5.65
1.26
1.01
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
1.60%
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
50130.10 million128.02 millionOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500539.68 million535.10 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.11 million109.95 millionOptionable

Recent News About These Companies

HC Wainwright Brokers Decrease Earnings Estimates for VKTX
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$3.09 +0.05 (+1.64%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$3.08 -0.01 (-0.49%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Amgen stock logo

Amgen NASDAQ:AMGN

$331.70 +2.61 (+0.79%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$331.99 +0.29 (+0.09%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$948.01 -26.95 (-2.76%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$950.10 +2.09 (+0.22%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$25.65 -0.83 (-3.15%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$25.68 +0.03 (+0.11%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$31.33 -0.25 (-0.79%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$31.37 +0.04 (+0.13%)
As of 05/8/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.